Disclosures: Chandana Thimme Gowda: Nothing to Disclose, MALLIKARJUNA SIRAGANAHALLI ESHWARAIAH: Nothing to Disclose, Nirmala Mavila: Nothing to Disclose, Jiaohong Wang: Nothing to Disclose, Maria Lauda Tomasi: Nothing to Disclose, Komal Ramani: Nothing to Disclose 1574 INTEGRATED HEPATOLOGY AND ADDICTION MEDICINE CONSULTATION FOR HOSPITALIZED PATIENTS WITH ALCOHOL USE DISORDER REDUCES FUTURE LIVER-RELATED DECOMPENSATING EVENTS Jay Luther 1 Paul George 2 Michael Butler 2 Prasanna Challa 2 Esperance Schaefer 3 Russell Goodman 1 Wei Zhang 2 , 1 Massachusetts General Hospital, 2 MGH, 3 BWH Background: While multiple factors contribute to rising mortality seen with alcohol-associated liver disease (ALD), one deficiency is clear: most patients with ALD are diagnosed at an advanced stage
Were talking about: The push to classify retatrutide as a biologic Why that could mean pricing in the $7,000/month range How LillyDirect is changing access to tirzepatide The two lane system that could define obesity treatment going forward And what this means for patients already struggling to stay on GLP-1 therapies If youve ever fought insurance, dealt with compounding disappearing, or felt like the system decides what youre allowed to have this one is for you
The drugs stay in the system a long time, about 4-6 weeks, after the last dose
Kale chips, a fruit bowl, homemade granola with yogurt, overnight oats or a savory Greek yogurt dip served with vegetables are all good options, she says
The MetroHealth System, Cleveland OH, IRB determined research using TriNetX as described in this study was not Human Subject Research, and IRB approval is not required (more details in the Supplementary Appendix)
